APLS
Apellis Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$41.03
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.0B | 781.4M | 396.6M | 75.4M |
| Cost of Revenue | 109.2M | 102.2M | 117.7M | 58.5M | 5.6M |
| Gross Profit | 996.1M | 901.5M | 663.6M | 338.1M | 69.8M |
| Operating Expenses | |||||
| R&D Expense | 286.4M | 295.9M | 327.6M | 354.4M | 387.2M |
| SG&A Expense | 544.8M | 550.3M | 501.1M | 500.8M | 277.2M |
| General & Admin Expense | — | — | 417.8M | 500.8M | 277.2M |
| Selling & Marketing Expense | — | — | 83.3M | — | — |
| Other Expenses | — | — | — | — | (288.0K) |
| Total Operating Expenses | 831.2M | 846.1M | 828.6M | 855.2M | 664.4M |
| Cost and Expenses | 940.1M | 948.4M | 946.3M | 913.7M | 670.0M |
| Operating Income (EBIT) | 165.2M | 55.4M | (165.0M) | (517.1M) | (594.6M) |
| Non-Operating | |||||
| Interest Income | 13.4M | 13.1M | 12.8M | 20.9M | 8.9M |
| Interest Expense | 43.6M | 44.3M | 40.4M | 29.6M | 32.6M |
| Net Interest Income | (30.2M) | (31.2M) | (27.6M) | (8.6M) | (23.7M) |
| Other Non-Op Income/Expense | (30.1M) | (31.3M) | (31.7M) | (9.4M) | (56.9M) |
| Non-Operating Income (excl Interest) | (10.5M) | (13.0M) | (8.7M) | (20.2M) | 24.3M |
| EBT (Pre-Tax Income) | 135.1M | 24.1M | (196.7M) | (526.5M) | (651.5M) |
| Income Tax Expense | 1.9M | 1.7M | 1.2M | 2.1M | 669.0K |
| Bottom Line | |||||
| Net Income | 133.3M | 22.4M | (197.9M) | (528.6M) | (652.2M) |
| Earnings from Cont. Ops | 133.3M | 22.4M | (197.9M) | (528.6M) | (652.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 134.2M | 22.4M | (197.9M) | (528.6M) | (652.2M) |
| Per Share | |||||
| Basic EPS | $1.06 | $0.18 | ($1.60) | ($4.45) | ($6.15) |
| Diluted EPS | $1.06 | $0.18 | ($1.60) | ($4.45) | ($6.15) |
| Revenue Per Share | $8.77 | $7.97 | $6.31 | $3.34 | $0.71 |
| Shares | |||||
| Basic Shares Outstanding | 126.0M | 126.0M | 123.9M | 118.7M | 106.1M |
| Diluted Shares Outstanding | 126.0M | 126.0M | 123.9M | 118.7M | 106.1M |
| Profitability Metrics | |||||
| EBITDA | 177.1M | 70.0M | (154.5M) | (495.2M) | (617.4M) |
| D&A | 1.4M | 1.6M | 1.8M | 1.7M | 1.5M |
| EBIT | 175.7M | 68.4M | (156.3M) | (496.9M) | (618.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026